Connecting public research developments with the private sector is one of IDIBELL’s strategic projects for the coming years. This was shared by Gabriel Capellá, director of the Bellvitge Biomedical Research Institute, during the Health Innovation Day event organized by the Hospitalet and Baix Llobregat Business Association.
The event provided an opportunity to present the Greenvia Labs project, the biomedical business incubator at the Bellvitge Health Campus, which is expected to launch in early 2027. The initiative is being launched with two key partners: IDIBELL, as the scientific partner to connect the incubator’s initiatives with the public research conducted on campus, and the Fornesa & Sala Group, as the developer of the physical space that will house the incubator. Once implemented, Cosymbio Labs, a company specializing in the implementation of research spaces, will act as the manager.
Still in the design phase, Greenvia Labs will be able to accommodate companies at different stages of their transition to the commercial market. As the director of IDIBELL explained, the spirit of the proposal is that the companies that host the incubator will contribute solutions to the major challenges of the Bellvitge Health Campus. In this regard, priority will be given to projects and companies that provide solutions in areas such as cancer, neuroscience, regenerative medicine, rare adult diseases, and advanced technology for invasive procedures.
The incubator is part of the initiatives of the Bellvitge Health Campus, which comprises the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL), the University of Barcelona (UB), the Emergency Medical Service (SEM), and the Delta Primary and Community Care Management (GAPiC Delta). This alliance is a national and international leader in healthcare, education, research, and biomedical innovation, and is also a key player in shaping the future Innovation and Health Biocluster of Hospitalet de Llobregat.
About IDIBELL
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center established in 2004 specialized in cancer, neuroscience, translational medicine, and regenerative medicine. It counts on a team of more than 1.500 professionals who, from 73 research groups, publish more than 1.400 scientific articles per year. IDIBELL is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona, and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).